Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ASH1L | Q9NR48 | 5/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Protionamide SCHEMBL30271512 | 0.81 | KDM4E (1.00) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| Protionamide SCHEMBL74572 | 0.81 | KDM4E (1.00) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| SCHEMBL28093033 | 0.77 | KDM4E (0.84) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| Ethionamide SCHEMBL12264086 | 0.76 | CYP1A2 (1.00) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| Ethionamide SCHEMBL12264084 | 0.76 | CYP1A2 (1.00) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| Ethionamide SCHEMBL12264091 | 0.76 | CYP1A2 (1.00) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| Ethionamide SCHEMBL12264093 | 0.76 | CYP1A2 (1.00) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| Ethionamide SCHEMBL12264085 | 0.76 | CYP1A2 (1.00) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| Ethionamide SCHEMBL27007 | 0.76 | CYP1A2 (1.00) | KDM4ELMNACYP3A4TSHRCYP1A2 | |
| Ethionamide SCHEMBL12264090 | 0.76 | CYP1A2 (1.00) | KDM4ELMNACYP3A4TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3038622-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
| EP-3265088-A1 | SREBP BLOCKERS FOR USE IN TREATING LIVER FIBROSIS, ELEVATED CHOLESTEROL AND INSULIN RESISTANCE | Medivation Technologies LLC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| CN-106029072-A | Heterocyclic compounds and methods of use | 麦迪韦逊技术股份有限公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-3038622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| WO-2015031650-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | CHAKRAVARTY SARVAJIT (US) | 2015-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRAS, VHL, ESRRB | KDM4E 3356/4885LMNA 2671/4885CYP3A4 2057/4885 |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | KDM4E 2233/4885LMNA 999/4885CYP3A4 484/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | KDM4E 2233/4885LMNA 999/4885CYP3A4 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.